Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS-5745 plus nivolumab versus nivolumab in unresectable or recurrent gastric or gastroesophageal junction adenocarcinoma
2016-001402-41Phase 2Terminated
- Sponsor
- Gilead Sciences
- Start
- Aug 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of andecaliximab, nivolumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Gilead Sciences. Started Aug 2016; status: terminated.
02
Drugs
andecaliximabnivolumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2016-001402-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001402-41.